

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (Original) A nucleic acid molecule comprising a first polynucleotide that comprises a nucleotide sequence chosen from:

- (a) SEQ ID NOS.:1-187, 375-484;
- (b) a polynucleotide encoding a polypeptide comprising an amino acid sequence chosen from SEQ ID NOS.:188-374;
- (c) a complementary polynucleotide comprising a complementary nucleotide sequence that is complementary to the first nucleotide sequence of (a); and
- (d) a biologically active fragment of any of (a) – (c); and,

wherein the nucleic acid molecule is an isolated molecule.

Claims 2 - 4 (Canceled)

Claim 5 (Original) The nucleic acid molecule of claim 1, further comprising a second polynucleotide.

Claim 6 (Original) The nucleic acid molecule of claim 5, wherein the second polynucleotide comprises a second nucleotide sequence encoding a secretory leader, and the secretory leader is a homologous or heterologous leader.

Claim 7 (Canceled)

Claim 8 (Currently Amended) A polypeptide comprising a first amino acid sequence chosen from:

- (a) SEQ ID NOS.:188-374;
- (b) a sequence encoded by one of SEQ ID NOS.:1-187, 375-484; and
- (c) [[an]] a biologically active fragment of (a) or (b);

wherein the polypeptide is an isolated molecule.

Claims 9 - 12 (Canceled)

Claim 13 (Original) The polypeptide of claim 8, further comprising a second amino acid sequence, wherein the second amino acid sequence is a secretory leader, the secretory leader is a homologous leader or a heterologous leader, and the first and second amino acid sequences are operably linked.

Claim 14 - 15 (Canceled)

Claim 16 (Currently Amended) The polypeptide of claim 8, ~~consisting essentially of~~  
wherein the active fragment comprises a mature polypeptide sequence.

Claim 17 (Currently Amended) A polypeptide of claim 8, wherein the fragment comprising comprises at least six contiguous amino acids ~~chosen from SEQ ID NOS.:188-374 or encoded by SEQ ID NOS.:1-187, 375-484 residues.~~

Claim 18 (Original) A vector comprising the nucleic acid molecule of claim 1 and a promoter that regulates the expression of the nucleic acid molecule.

Claim 19 - 22 (Canceled)

Claim 23 (Currently Amended) A recombinant host cell comprising a cell and the nucleic acid of claim 1, ~~the polypeptide of claim 8, or the vector of claim 18.~~

Claim 24 - 29 (Canceled)

Claim 30 (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and ~~an isolated polynucleotide, wherein the polynucleotide comprises a nucleic acid sequence chosen from SEQ ID NOS.:1-187, 375-484~~ molecule of claim 1.

Claim 31 (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and ~~an isolated polypeptide, wherein the a polypeptide comprises an amino acid sequence chosen from SEQ ID NOS.:188-374 of~~ claim 8.

Claim 32 (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the vector of claim 18.

Claim 33 (Canceled)

Claim 34 (Currently Amended) A host cell composition comprising:

- (a) a recombinant host cell of claim 23; and
- (b) a pharmaceutically acceptable carrier; and
- (c) ~~the nucleic acid of claim 1, the polypeptide of claim 8, and/or the vector of claim 18.~~

Claim 35 (Original) A method of producing a recombinant host cell comprising:

- (a) providing a vector comprising the nucleic acid molecule of claim 1; and
- (b) allowing a cell to come into contact with the vector to form a recombinant host cell transfected with the nucleic acid molecule.

Claim 36 (Original) A method of producing a polypeptide comprising:

- (a) providing the nucleic acid of claim 1; and
- (b) expressing the nucleic acid molecule in an expression system to produce the polypeptide.

Claims 37 - 40 (Canceled)

Claim 41 (Original) A polypeptide produced by the method of claim 36.

Claim 42 - 43 (Canceled)

Claim 44 (Currently Amended) An antibody or a biologically active fragment thereof specifically recognizing, binding to, and/or modulating the biological activity of ~~at least one molecule chosen from a polypeptide encoded by a nucleic acid molecule of claim 1, a polypeptide of claim 8, and a fragment of either of these.~~

Claims 45 - 48 (Canceled)

Claim 49 (Original) A fusion molecule comprising a first polypeptide that comprises an amino acid sequence of a therapeutic molecule chosen from SEQ ID NOS.:188-374, a polypeptide encoded by a polynucleotide chosen from SEQ ID NOS.:1-187, 375-484, or a fragment of any of these, and a second polypeptide that comprises an amino acid sequence of a fusion partner.

Claims 50 -51 (Canceled)

Claim 52 (Currently Amended) A method of determining the presence of ~~the a~~ nucleic acid molecule of ~~one or more of SEQ ID NOS.:1-187, 375-484, or a complement thereof~~ claim 1 in a sample comprising:

- (a) providing a complement to the nucleic acid molecule ~~or providing a complement to the complement of the nucleic acid molecule;~~
- (b) allowing the molecule to interact with the sample; and

(c) determining whether interaction has occurred.

Claim 53 (Currently Amended) A method of determining the presence of ~~the-a~~ polypeptide of ~~one or more of SEQ ID NOS.:188-374, or fragment thereof, claim 8~~ in a sample, comprising:

- (a) providing an antibody that specifically binds to or interfere with the activity of the polypeptide;
- (b) allowing the antibody to interact with the polypeptide in the sample, if any; and
- (c) determining whether interaction has occurred.

Claim 54 (Canceled)

Claim 55 (Currently Amended) A method of determining the presence of a specific antibody to a ~~polypeptide encoded by a nucleotide of SEQ ID NOS.:1-187, 375-484, or fragment thereof; or the polypeptide of one or more of SEQ ID NOS.:188-374, or fragment thereof, claim 8~~ in a sample, comprising:

- (a) providing the polypeptide;
- (b) allowing the polypeptide to interact with a specific antibody in the sample, if present; and
- (c) determining whether interaction has occurred.

Claims 56 - 63 (Canceled)

Claim 64 (Currently Amended) A method for treating a tumor in a subject comprising:

- (a) providing a pharmaceutical composition containing a polypeptide chosen from any one of claims 8, 13, or 41, and an active fragment of any of these; and a pharmaceutically acceptable carrier 31; and
- (b) administering the composition to the subject.

Claims 65 - 69 (Canceled)

Claim 70 (Currently Amended) A method of treating a tumor in a subject comprising:

- (a) providing a first composition comprising polypeptide encoded by a nucleotide of SEQ ID NOS.:1-187, 375-484, or fragment thereof; or the polypeptide of one or more of SEQ ID NOS.:188-374, or fragment thereof a pharmaceutical composition of claim 31;
- (b) providing a second composition comprising an different anti-cancer agent different from the polypeptide of (a); and
- (c) administering the first and second compositions to the subject.

Claims 71 - 73 (Canceled)

Claim 74 (Currently Amended) A method of treating an immune disease in a subject comprising:

- (a) providing a first composition comprising ~~polypeptide encoded by a nucleotide of SEQ ID NOS.:1-187, 375-484, or fragment thereof; or the polypeptide of one or more of SEQ ID NOS.:188-374, or fragment thereof~~ a pharmaceutical composition of claim 31;
- (b) providing a second composition comprising ~~an~~ different agent effective in treating an immune disease ~~different from the polypeptide of (a)~~; and
- (c) administering the first and second compositions to the subject.

Claim 75 (Canceled)

Claim 76 (Currently Amended) A method of treating a metabolic disease in a subject comprising:

- (a) providing a first composition comprising ~~polypeptide encoded by a nucleotide of SEQ ID NOS.:1-187, 375-484, or fragment thereof; or the polypeptide of one or more of SEQ ID NOS.:188-374, or fragment thereof~~ a pharmaceutical composition of claim 31;
- (b) providing a second composition comprising ~~an~~ different agent effective in treating a metabolic disease ~~different from the polypeptide of (a)~~; and
- (c) administering the first and second compositions to the subject.

Claim 77 (Canceled)

Claim 78 (Currently Amended) A method of treating a degenerative disease in a subject comprising:

- (a) providing a first composition comprising ~~polypeptide encoded by a nucleotide of SEQ ID NOS.:1-187, 375-484, or fragment thereof; or the polypeptide of one or more of SEQ ID NOS.:188-374, or fragment thereof~~ a pharmaceutical composition of claim 31;
- (b) providing a second composition comprising ~~an~~ different agent effective in treating a degenerative disease ~~different from the polypeptide of (a)~~; and
- (c) administering the first and second compositions to the subject.

Claim 79 (Canceled)

Claim 80 (New) A nucleic acid molecule of claim 1, wherein the biologically active fragment comprises a nucleotide sequence encoding a mature protein.